ASC demand for Omeros' phenylephrine and ketorolac intraocular solution, Omidria, hit a record high in the fourth quarter of 2018.
What you should know:
1. Omeros' preliminary total and Omidria 1 percent/0.3 percent revenues for the fourth quarter are expected to reach $22 million, a year-over-year increase of $13.8 million and a quarterly increase of $4.6 million.
2. The growth reflects strong demand for Omidria from ASCs and hospitals
3. Pass-through reimbursement for Omidria was reinstated Oct. 1, 2018, spurring higher demand.
4. Units sold by wholesalers to ASCs and to hospitals also hit a record high in the fourth quarter of 2018.
5. Omeris is using growing revenues from Omidria to advance pipeline progress, including its phase 3 program in hematopoietic stem cell transplant-associated thrombotic microangiopathy.